MedTrace Logo

Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation

NCT04575779 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 31

Last updated 2023-02-01

No results posted yet for this study

Summary

This study focuses on the basis for current immunosuppressive strategies in patients undergoing allogeneic haematopoietic stem cell transplantation at the bone marrow transplantation unit in Ain Shams university hospitals. It discusses whether there is room for improving both the monitoring and the delivery of pharmacologically mediated immunosuppression in this population of patients. Our study will try to determine whether CsA administration at a daily dose of 3 mg/kg/day intravenously (IV) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.

Conditions

  • Allogenic Bone Marrow Transplantation

Interventions

DRUG

Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h

To determine whether administering CsA at a dailydose of 3 mg/kg/day intravenously(i.v.) in 2 hrs (short infusion) twice-daily will achieve C2 blood levels of at least 800 mg/l and whether it will be feasible and safe or not.

Sponsors & Collaborators

  • Shaymaa Mohammed El-Awady

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-10
Primary Completion
2021-04-04
Completion
2022-05-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04575779 on ClinicalTrials.gov